Because CD38 is expressed constitutively at high levels on human antibody-secreting plasmablasts and plasma cells and is inducible on several immune cell subsets upon activation, CD38 has been considered as a potential therapeutic target in autoantibody-driven diseases such as SLE [15], autoimmune encephalitis [16,17], and autoimmune hemolysis [18]. This evidence concerns the gene CD38 and systemic lupus erythematosus.